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A B S T R A C T
To date Bordetella petrii has infrequently been identiﬁed within the clinical setting likely due to the
asaccharolytic nature of this organism. We present a case of B. petrii recovered on two separate events in
a patient with adult cystic ﬁbrosis experiencing chronic pansinusitis.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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We present a 41-year old female with a 20 plus year history of
nasal obstruction and chronic sinusitis. Her clinical history
indicated velopharyneal insufﬁciency (incomplete closure of the
velopharyngeal sphincter between the oropharynx and the
nasopharynx), severe gastroparesis, signiﬁcant gastric reﬂux and
asthma contributed to a conﬁrmed cystic ﬁbrosis mutation, DF508
gene. Individuals diagnosed with adult cystic ﬁbrosis frequently
experience gastroparesis, asthma and chronic sinusitis [1,2].
Historically, the patient underwent several surgical interven-
tions, multiple rounds of antimicrobials, decongestants, antihis-
tamines, topical and oral steroids without improvement of her
diffuse pansinusitis. In an attempt to alleviate her chronic sinusitis,
revision endoscopic sinus surgery with septoplasty and a
turbinectomy was performed during early 2014 (day 0). A right
maxillary sinus tissue specimen was sent for aerobic bacterial
culture, which was incubated aerobically only with 5% CO2 at 35 8C.
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4.0/).organisms. Twenty-four hours post-incubation, moderate growth
of a tiny Gram-negative colony was noted on trypticase soy agar
with 5% sheep blood (Becton, Dickinson and Company, Franklin
Lakes, NJ). No other organisms were recovered. By 48 h, growth
was noted on the MacConkey agar (Becton, Dickinson and
Company, Franklin Lakes, NJ). The isolate was identiﬁed by the
Bruker Biotyper MALDI-TOF MS system (Bruker Daltonics Inc.,
Billerica, MA) as Bordetella petrii (score 2.13; highly probable
species identiﬁcation). Since the organism had not been validated
by this method, the isolate was tested by the Microscan NBPC30
panel for oxidase positive organisms (Siemens Medical Solutions
USA, Inc., Malvern, PA) and the Remel RapID NF PLUS System
(Thermo Fisher Scientiﬁc Remel Products, Lenexa, KS). The NBPC30
panel identiﬁed the organism as Alcaligenes species (00064326)
79.12%. The RapID system identiﬁed the organism as Alcaligenes
xylosoxidans (210606) Implicit. Both B. petrii and Alcaligenes species
are asachrolytic organisms and part of the Alcaligenaceae family
[3]. The isolate exhibited the following phenotypic characteristics:
non-motile; oxidase, catalase, and nitrate positive; urea negative;
malate, tartrate and citrate positive, this phenotype is consistent
throughout literature [3–6]. For more stringent conﬁrmation, 16S
rRNA sequencing was performed at ARUP laboratories and
provided an identiﬁcation of B. petrii (Salt Lake City, UT). No
standard antibiotic susceptibility guidelines are deﬁned for this
organism; however, antimicrobial susceptibility test (AST) results
for the two isolates are shown in Table 1 for epidemiologic strain
differentiation.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Table 1
Results of antimicrobial susceptibility testing for both isolate one and two.
Antimicrobial agent Isolate one Isolate two
MIC (mg/mL) MIC (mg/mL)
Ampicillin >16 >16
Ampicillin/sulbactam 16/8 16/8
Amikacin 16 16
Amoxicillin/K Clavulanate 8/4 8/4
Gentamicin 8 4
Imipenem 4 4
Levoﬂoxacin 2 2
Ciproﬂoxacin >2 >2
Moxiﬂoxacin 4 4
Gatiﬂoxacin 2 2
Norﬂoxacin >8 >8
Piperacillin/tazobactam 16/4 16/4
Tetracycline 4 4
Ticarcillin/K clavulanate 16 16
Tobramycin 4 4
Trimethoprim/sulfamethoxazole 2/38 2/38
Aztreonam >16 >16
Cefepime >16 >16
Cefuroxime >16 >16
Cefazolin >16 >16
Cephalothin >16 >16
Cefoxitin >16 >16
Cefotetan >32 >32
Cefotaxime >32 >32
Ceftazidime 8 >16
Ceftriaxone >32 >32
Meropenem >8 >8
Chloramphenicol >16 >16
Meropenem 4 4
Piperacillin 16 16
Nitrofurantoin >64 >64
Microscan NBPC30 for oxidase positive Gram-negative bacteria.
L. Biederman et al. / IDCases 2 (2015) 97–9898The patient was not treated speciﬁcally for B. petrii as
improvement was noted with the standard post-operative
antimicrobial regime of various corticosteroids, oral erythromycin
(250 mg/mL, four times a day) and oral cefdinir (300 mg, every
12 h for 10 days). Based on the AST proﬁle of the isolate (Table 1),
particularly ceftriaxone and cefotaxime with minimal inhibitory
concentrations (MICs) >32 mg/mL, one would expect the organism
to be resistant to cefdinir, another 3rd generation cephalosporin.
Erythromycin was not tested for this isolate but other studies have
shown resistance toward 3rd generation cephalosporins and also
toward erythromycin [4,7,8]. One study indicated that piperacillin-
tazobactam is the only effective treatment for B. petrii [7].
At outpatient follow-up (29 days post-procedure), she under-
went endoscopy with collection of a second sinus culture via
ﬂocked swab. The direct Gram-stain of the sinus specimen showed
few white-blood cells and no organisms. Again, moderate growth
of B. petrii (MALDI-TOF score 2.00; secure genus identiﬁcation,
probable species identiﬁcation) occurred, indicating that the initial
post-operative antimicrobial therapy did not eradicate B.
petrii. There was very light growth of normal respiratory ﬂora.
Discussion
There are nine different Bordetella species of these B. petrii is the
only species that does not exhibit a human host tissue tropism
[4,6]. This species was ﬁrst identiﬁed in 2001 after isolation from an
anaerobic bioreactor enriched with river sediment [6]. Clinically, B.
petrii has rarely been isolated from clinical specimens and has not
been well described as a pathogen. This is likely due to the
asacchrolytic nature of the organism in addition to the B. petrii not
being contained in most automated identiﬁcation system libraries.There has been a limited number of case reports with B. petrii deﬁned
as the etiologic agent [4,5,7–10]. B. petrii has been implicated as the
causative agent in cases of mandibular osteomyelitis, chronic
suppurative mastoiditis, chronic pulmonary obstructive disease and
persistent bronchiectasis [4,8–10]. Importantly, it has been previ-
ously isolated from in cystic ﬁbrosis patients [5,7].
Because it is uncommon, or likely misidentiﬁed, accurate
identiﬁcation of B. petrii represents a challenge for traditional
automated identiﬁcation systems. These biochemical or enzymatic
systems are only marginally effective, due to the lack of a distinct
biochemical carbohydrate proﬁle as well as limited or uncurated
databases. Not only was B. petrii mis-identiﬁed by MicroScan
(NBPC30) and rapID panels in the two described occasions for this
patient, but it was also misidentiﬁed in other reported cases
[10]. Studies show that Bordetella species are closely related to
Achromobacter (Algaligenes) species [6,11]. The case patient had
two sinus isolates identiﬁed three years prior as Achromobacter
species (90%) by the BD Phoenix NMIC/ID-124 panel (Becton-
Dickinson, Sparks, MD). Unfortunately, these isolates are no longer
available to determine if they were misidentiﬁed. The gold
standard method for identiﬁcation of B. petrii is 16S rRNA
sequencing [4,8,10]. At that time the patient was treated post-
operatively with 1000 mg of cefazolin (MIC > 16 mg/mL), indicat-
ing inadequate coverage.
The importance of B. petrii as a clinical pathogen has not been
well established; however, it has been described in cystic ﬁbrosis
patients [1,2,5,7]. B. petrii has been demonstrated to persist despite
treatment in patients, as was potentially noted with her previous
isolates of Achromobacter species [7,10]. By using the MALDI-TOF
methodology the clinical laboratory can achieve not only quicker
but more accurate organism identiﬁcations. More accurate
identiﬁcation can lead to more appropriate treatment and provide
insight into the true clinical prevalence of organisms like B. petrii,
which have been shown to be resilient colonizers especially within
cystic ﬁbrosis patients [7,10].
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